Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma.

Abstract

BACKGROUND/AIM AXL (anexelekto) has been explored as a potential novel therapeutic target for non-small cell lung carcinoma (NSCLC) but its activation status has not been evaluated in NSCLC. PATIENTS AND METHODS We first immunolocalized the phosphorylated form of AXL in 112 lung adenocarcinoma cases and subsequently evaluated the anti-neoplastic effects… (More)

Topics

Cite this paper

@article{Iida2014ActivationOA, title={Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma.}, author={Shinya Iida and Yasuhiro Miki and Takashi Suzuki and Kazushige Mori and Mikiyoshi Saito and Hiromichi Niikawa and Takashi Kondo and Hisafumi Yamada-Okabe and Hironobu Sasano}, journal={Anticancer research}, year={2014}, volume={34 4}, pages={1821-7} }